Compare HTH & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTH | STOK |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2003 | 2019 |
| Metric | HTH | STOK |
|---|---|---|
| Price | $38.78 | $34.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $37.50 | $34.50 |
| AVG Volume (30 Days) | 439.6K | ★ 520.1K |
| Earning Date | 05-01-2026 | 04-15-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | ★ 51.72 | 30.67 |
| EPS | ★ 2.64 | 0.85 |
| Revenue | ★ $152,188,000.00 | $36,555,000.00 |
| Revenue This Year | N/A | $430.19 |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | ★ $14.69 | $40.34 |
| Revenue Growth | 15.52 | ★ 316.34 |
| 52 Week Low | $27.35 | $5.35 |
| 52 Week High | $40.41 | $38.62 |
| Indicator | HTH | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 57.52 | 60.72 |
| Support Level | $38.05 | $30.68 |
| Resistance Level | $39.94 | $34.67 |
| Average True Range (ATR) | 1.02 | 2.27 |
| MACD | -0.17 | 0.27 |
| Stochastic Oscillator | 38.40 | 92.67 |
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.